Partners for health A joint health strategy for the London Borough of Brent

A joint initiative from Brent Council, Brent and Harrow Health Authority and Brent and Harrow Family Health Services AuthoritySIGLEAvailable from British Library Document Supply Centre- DSC:OP-LG/7609 / BLDSC - British Library Document Supply CentreGBUnited Kingdo

Report of the independent inquiry into the care and treatment of AB

Includes bibliographical references. Title from cover. Includes 1 unbound leaflet, 'Action plan following the recommendations'Available from British Library Document Supply Centre- DSC:m03/19826 / BLDSC - British Library Document Supply CentreSIGLEGBUnited Kingdo

Report of the independent inquiry into the care and treatment of WM

Presented to Brent and Harrow Health Authority and London Borough of HarrowAvailable from British Library Document Supply Centre-DSC:m01/33183 / BLDSC - British Library Document Supply CentreSIGLEGBUnited Kingdo

The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.

Colorectal cancer is the fourth most commonly diagnosed cancer in the UK after breast, lung and prostate cancer. People with metastatic disease who are sufficiently fit are usually treated with active chemotherapy as first- or second-line therapy. Targeted agents are available, including the antiepidermal growth factor receptor (EGFR) agents cetuximab (Erbitux(®), Merck Serono UK Ltd, Feltham, UK) and panitumumab (Vecitibix(®), Amgen UK Ltd, Cambridge, UK).This report is freely available online. Click on the Additional Link above to access the full-text via the publisher's site